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Homocysteine plasma levels as a marker of clinical 
severity in septic patients
Nível plasmático de homocisteína: marcador de gravidade em 
pacientes sépticos?
ORIGINAL ARTICLE
INTRODUCTION
Homocysteine (Hmc) is an intermediate amino acid containing a sul-
phydryl radical. It is formed by methionine amino acid conversion into 
cysteine. About 70 to 80% of plasma Hmc is protein-bound, mainly al-
bumin.(1) Only 7% free homocysteine appears as the reduced form.(2) This 
amino acid is considered a risk marker for cardiovascular, particularly cor-
onary, diseases.(3-5) The mechanisms involved on Hmc vascular damage are 
controversial, however they include increased oxidative stress,(6)  enhanced 
thrombogenisis,(7) endothelial dysfunction,(8) and smooth muscle cells 
mitosis interference.(9,10) For at least forty years, changed homocysteine 
plasma levels have been indicative of a systemic disease. 
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ABSTRACT
Objective: Homocysteine and sepsis 
are both associated with inflammation 
and endothelial activation. Therefore this 
study was aimed to evaluate if the plasma 
homocystein level is related with the sep-
tic patient clinical severity.
Methods: Severe sepsis or septic shock 
patients, with less than 48 hours from 
organ dysfunction start, were admitted 
to this prospective observational study. 
Homocysteine levels were determined by 
the time of study admission and then on 
the Days 3, 7 and 14. The homocysteine 
association with the Sequential Organ 
Failure Assessment (SOFA) score was 
evaluated using the Sperman test, and 
its association with mortality using the 
Mann-Whitney test. A p<0.05 value was 
considered statistically significant.
Results: Twenty one patients were 
enrolled, and 60 blood samples were 
collected to measure total homocysteine 
[median 6.92 (5.27 – 9.74 μmol/L)]. The 
Sperman correlation test showed no asso-
ciation between homocysteine and SOFA 
( r=0.15 and p=0.26). Also no correlation 
was found for the homocysteine level by 
the study admission time and the differ-
ence between the Day 3 SOFA score versus 
by study admission (deltaSOFA) (r=0.04 
and p=0.87). Homocysteine varia tion 
between the Day 3 and the study admis-
sion (deltaHmc) and SOFA score varia-
tion in the same period were not correla-
ted (r=-0.11 and p=0.66). Homocysteine 
by the study admission was not correlated 
with death in intensive care unit rate (p= 
0.46) or in-hospital death rate (p = 0.13). 
This was also true for deltaHmc (p=0.12 
and p=0.99, respectively). 
Conclusion: Baseline homocysteine 
levels and its variations within the first 
dysfunction days were not related with 
septic patients’ worsened organ function 
parameters or mortality. 
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Recently more attention was drawn to Hmc due to 
the growing body of evidence published on this amino 
acid connection with atherosclerotic disease.(3-5,11-13) 
Intima (endothelial layer) degenerative processes, as 
inflammation and thrombogenesis, are listed among 
the possible Hmc-related endothelial injury patho-
physiology.(14,15) 
The atherosclerotic process endothelial dysfunc-
tion, related with Hmc plasma levels changes, has 
similarities with the sepsis’ endothelial dysfunction. 
Sepsis is a systemic syndrome associated with in-
creased inflammatory mediators as cytokines, arac-
donic acid derivatives, oxygen reactive species, nitric 
oxide, intracellular adhesion molecule (ICAM), and 
endothelial leucocyte adhesion molecule (ELAM), 
and endothelial function changes are a relevant part 
of its pathophysiology.(16) Therefore, such a hyper-
metabolic, pro-inflammatory and pro-thrombotic 
condition as sepsis would be an appropriate scenario 
for Hmc levels changes. 
Given this, the possible relationship between sep-
sis severity (i.e., the organ dysfunction degree) and 
Hmc plasma levels could be questioned. Therefore 
this study was aimed to evaluate Hmc plasma levels 
in septic patients and investigate its correlation with 
organ dysfunction both presence and severity. 
METHODS
This was a prospective observational clinical trial 
conducted in the intensive care unit of a tertiary uni-
versity hospital. The study was approved by the insti-
tution’s Ethics Committee, and patients were enrolled 
upon informed consent form signature. 
Patients aged 18 years or more, diagnosed severe 
sepsis or septic shock and less than 48 hours organ 
dysfunction, were enrolled. Severe sepsis was defined 
as a suspected infective focus and at least two 1992 
consensus’(17) systemic inflammatory response criteria, 
plus at least one organ dysfunction. Septic shock was 
defined as hypotension refractory to volume replace-
ment and requiring vasopressor amines. Dysfunction 
was considered as hypotension, partial oxygen pres-
sure and inspired oxygen fraction ratio (PaO2/FiO2) 
≤ 250, metabolic acidosis with lactate changes, plate-
lets count below 100,000 cells/mm3, total bilirubin 
above 2 mg/dL, urinary output lower than 0.5 mL/
hour although appropriate volume replacement, and 
depressed consciousness level. These dysfunctions 
should be clearly secondary to the septic process. Pa-
tients developing acute renal failure during their stay 
were excluded, due to interference with methionine 
metabolism. Plasma homocysteine level was age-cor-
rected for ≥ 70 year old patients. 
The demographic and sepsis characteristics and 
the Acute Physiological Chronic Health Evaluation II 
(APACHE II) score(18) were recorded for all patients. 
The Sequential Organ Failure Assessment (SOFA) 
score was used for organ dysfunction follow-up.(19) 
Blood samples for Hmc levels measurement were 
drawn by the admission and then after 3, 7 and 14 
days. The patients were followed from their intensive 
care unit (ICU) admission to 28 days after enroll-
ment, for mortality assessment.
The samples were drawn from a peripheral vein or 
artery, with the patient laying in supine position and 
less than 3 minutes tourniquet, after 8 hours fasting. 
Following collection the samples were placed in EDTA 
tubes and packaged in ice and immediately transferred 
to the laboratory. Special attention was given to fast 
transference, in order to prevent red blood cells to 
change Hmc levels. After separated, the plasma was 
frozen at -20ºC until the dosage time.
Plasma Hmc levels were measured with a high per-
formance liquid chromatography method [Pfeiffer 
et al.(20)]. All chemicals were obtained from Sigma 
Chemical Co. The results are expressed as μmol/L.
Hyper-homocysteinemia was categorized as: mod-
erate (15 to 30 μmol/L), intermediate (30 to 100 
μmol/L), and severe (> 100 μmol/L).(21) The correla-
tion between homocysteine and SOFA variables was 
checked with the Spearman’s test. In addition, ho-
mocysteine levels were also expressed as logarithm, 
and evaluated with the Pearson’s correlation test. Ad-
ditionally, the homocysteine level by the admission 
time, the between the 3rd and 1st days homocysteine 
level variation (deltaHmc), the SOFA scores varia-
tion between the 3rd and 1st day (deltaSOFA) (both 
expressed as absolute variation) were related, and this 
last analyzed both as continuous or categorical (wors-
ened versus improved) variable. Unchanged SOFA 
score (deltaSOFA = 0) was considered as worsened, as 
suggests unfavorable clinical outcome. 
The categorical results were expressed as percent-
age, and the continuous variables as mean and stan-
dard deviation (minimum-maximum), or median 
(interquartile 25%-75%). For the survivors versus 
non-survivors comparison, the Mann-Whitney test 
was used. P<0.05 results were considered statistically 
significant.
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RESULTS
Twenty one patients (11 male, 10 female) mean 
age 43.9 ±19.38 years (17-78 years) and APACHE II 
18.19 ± 8.23 (2-35) were admitted to the study. Pul-
monary was the main infective focus, with pneumonia 
diagnosed in 71.43% patients, followed by abdomi-
nal infection (47.62%) and urinary tract infection 
(33.3%). Severe sepsis was diagnosed in 33.3% of the 
patients, and septic shock in 66.5%. Mean admission 
time organ dysfunctions were 2.19 ± 0.87 (1-4 dys-
functions), and 76.19% of the patients had two or 
more dysfunctions. Mean first day SOFA was 7.48 ± 
3.76 (1 to 4). ICU stay mortality rate was 23.8%, and 
the 28 days mortality 28.6%. Overall patients’ data 
are shown on table 1.
Sixty samples were drawn for Hmc measurement, 
with a median 6.79 (5.07-9.77) μmol/L for all collec-
ted samples. The female subjects median was 9.3045 
(5.73-13.41) μmol/L, and male subjects 6.97 (4.76-
8.63) μmol/L, p = 0.28. Median Hmc levels for each 
sampling day, and mean SOFA scores are shown on 
table 2.
No association was found between the study admis-
sion day (D0) homocysteine levels and the outcomes 
discharge from ICU or death (non-survivors: 5.06 
(4.76-9.80) and survivors: 8.06 (5.79-9.86); p=0.46), 
or in-hospital mortality (5.45 (4.71-8.99) versus 8.64 
(6.83-10.03) for non-survivors and survivors, respec-
tively; p = 0.13). Even when deltaHmc was considered, 
no correlation with the outcome was found, neither 
for ICU mortality (non-survivors: -7.25 (-7.50-1.05) 
versus survivors: -0.70 (-3.45- -0.67); p=0.12) nor for 
in-hospital mortality (non-survivors: -0.77 (-7.25-
0.42) versus survivors: -1.09(-6.00-0.30); p=0.99). 
Homocysteine levels were not correlated with the 
sampling day SOFA (r=-0.15 and p=0.26) (Figure 
1). This was not changed by logarithmic homocyste-
ine expression (r=-0.15; p=0.23). No correlation was 
found for the study admission homocysteine and del-
taSOFA (r=0.04 and p=0.87) (Figure 2). Even when 
deltaSOFA was categorically evaluated, no difference 
was found for favorable outcome (8.19 (5.7-10.0) 
subjects and those who worsened (7.8 (5.3-10.8), 
Table 2 - Septic patients’ plasma homocysteine levels and severity 
Variable Day 0 
(N=21)
Day 3 
(N=19)
Day 7 
(N=15)
D 14 
(N = 5)
Overall
Hmc (μmol/L) 7.94 (5.33 - 9.91) 6.53 (4.36 – 8.94 7.49 (5.12 – 11.62) 5.40 (4.64 – 9.14) 6.79 (5.07 - 9.77)
SOFA 7.62 ± 3.72 5.63 ± 3.05 4.6 ± 2.5 2.80 ± 1.92
Hmc – homocysteine; SOFA – Sequential Organ Failure Assessment. Results expressed as median (25-75%) and mean ± standard deviation.
Table 1 – Population characteristics 
Variable Result
Male gender 52.38
Age (years) 43.9 ± 19.38
APACHE II 18.19 ± 8.23
Admission SOFA 7.48 ± 3.76
SOFA D3
Categorization
Severe Sepsis 33.3%
Septic Shock 66.7%
Focus 
Respiratory tract infection 71.43%
Abdominal infection 47.62%
Urinary tract infection 33.3%
Mortality
ICU 23.8%
28 days 28.6%
Apache – Acute Physiological Chronic Health Evaluation; SOFA – Se-
quential Organ Failure Assessment; ICU – intensive care unit. Results 
expressed as percent or mean ± standard deviation.
SOFA – Sequential Organ Failure Assessment.
Figure 1- Serum homocysteine levels and Sequential Organ 
Failure Assessment (SOFA) score correlation, considering all 
study days. Spearman (r = -0.15 e p = 0.26).
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p=0.86. Also, no association could be shown for del-
taHmc and organ dysfunctions results, as measured by 
variation of SOFA score in the same period (r=-0.11; 
p = 0.66) (Figure 3).
SOFA – Sequential Organ Failure Assessment.
Figura 2 – Serum homocysteine levels and Sequential Organ 
Failure Assessment (SOFA) score variation correlation, be-
tween Day 3 and study admission day. Spearman (r = 0.04; 
p = 0.87).
SOFA – Sequential Organ Failure Assessment.
Figure 3 – Day 3 and study admission day serum homocys-
teine levels and Sequential Organ Failure Assessment (SOFA) 
score correlation, for the same period. Spearman (r = -0.11; 
p = 0.66).
DISCUSSION
No homocysteine and septic disease severity cor-
relation, as evaluated by SOFA score or mortality was 
shown in this study. 
This frustrated our initial expectations. Homocys-
teine has been correlated with cardiovascular diseases 
due to atherosclerosis patients’ high plasma levels. 
This pathophysiology appears to involve endothelial 
dysfunction related to oxidative stress, thrombogene-
sis and endothelial changes.(14,22) Similarly, endothelial 
injury has a cornerstone role in sepsis pathophysiolo-
gy. During the sepsis development, inflammation-co-
agulation circuit and reduced fibrinolysis are directly 
related with organ dysfunctions in critical patients. 
This would be due to intravascular coagulation which 
would reduce the microcirculatory flow, perpetuating 
the hypoperfusion endothelial dysfunction and conse-
quently increasing inflammatory response.(16,23) There-
fore, the evaluation of plasma total homocysteine lev-
els and its correlation with SOFA values was expected 
to provide a rational for these parameters connection 
with organ changes and the possible homocysteine in-
volvement in endothelial function and sepsis patho-
physiology. 
Although many studies correlate homocyste-
ine with cardiovascular and cerebrovascular diseas-
es,(3,5,10-13,21) little evidence of homocysteine role in 
septic patients pathophysiology is found in the liter-
ature. The septic shock endothelial lesion may lead, 
among other dysfunctions, to acute respiratory dis-
tress syndrome (ARDS) and acute lung injury (ALI), 
which are frequent in septic patients.(24) Using this 
study rational, i.e., the correlation between hyper-
homocysteinemia and hypercoagulability, Tsangaris 
et al. conducted a trial where plasma homocysteine 
levels also failed to correlate with worse outcome 
ARDS and ALI patients.(25) This agrees with our re-
sults. 
This failure to find a correlation may be related to 
the sample size, the studied population, homocysteine 
metabolism aspects, septic shock metabolic changes, 
nutritional factors or the study design itself.
This study has strengths. Serial homocysteine 
plasma sampling by the admission, 3rd, 7th and 14th 
days allowed analyzing the results over the time. We 
should also emphasize that homocysteine values varia-
tions could come from long time sampling (above one 
month), different measurement and drawing tech-
niques, and inter-individual fluctuations. This was 
prevented by samples draws within up to 15 days, 
with 3-7 days interval. The same homocysteine eval-
uation technique was used for all patients, and one 
single laboratory. The blood draws were always com-
pliant to the consensual techniques for homocysteine 
analysis. The analysis were independently performed 
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inter-individually, and dependently in a same subject, 
thus reducing eventual population variation bias. It 
should also be considered that the analysis evaluated 
the homocysteine levels correlation with the organ 
dysfunction marker, SOFA, and not the isolated ho-
mocysteine levels in each subject. 
As weaknesses, one should emphasize the small 
number of patients, inclusion of patients older than 
60 years, and restricted to homocysteine plasma anal-
ysis. Homocysteine is stable in a control population. 
In an Australian study, the homocysteine serum levels 
were shown to have little fluctuation until the sixties, 
with a subsequent linear 1 μmol/L per decade change. 
Stable high creatinina values patients (chronic renal 
failure) also had a linear relationship, 148 μmol/L/
(μmol/L).(26)  This piece of information was used in 
this our study to correct total homocysteine levels. 
This extrapolation may be considered bias. How-
ever, this was true only for three patients (age above 
60 years) two of them with chronic renal failure (i.e., 
two of the three above 60 years old patients), corre-
sponding to only 15% of the patients, and 13% of 
the collected samples. Another possible limitation is 
that homocysteine is related to its metabolic pathway 
co-factors levels. Two of these co-factors, which could 
be changed during the metabolic response to septic 
disease, would be folates and complex B vitamins, co-
factors for both homocysteine methylation (cobala-
min) and cystatione (vitamin B6) production.(27-29) 
Considering that sepsis is a hypermetabolic condi-
tion, these complements changes could influence with 
homocysteine levels. Even nutritional offer of these 
factors could have a role. Unfortunately, the serum 
analyses were restricted to homocysteine.
CONCLUSION
Our results suggest no correlation between serum 
homocysteine levels and SOFA score or mortality. As 
SOFA is well accepted as a septic patients organ dys-
function marker, we conclude that it was not possible 
to correlate serum homocysteine levels with worsened 
organ systems function parameters, likely indicating 
that homocysteine is not involved in sepsis endothe-
lial dysfunction pathophysiology. 
RESUMO
Objetivo: Homocisteína e a sepse estão ambos associados 
à inflamação e ativação endotelial. O objetivo desse estudo foi 
verificar se o nível plasmático de homocisteína está relacionado 
à gravidade do quadro séptico. 
Métodos: Estudo clínico, prospectivo e observacional, in-
cluindo pacientes com sepse grave ou choque séptico com me-
nos de 48 horas de instalação da disfunção orgânica. Os níveis 
de homocisteína foram determinados no dia da inclusão no es-
tudo e nos dias 3, 7, 14. A associação entre homocisteína com o 
escore Sequential Organ Failure Assessment (SOFA) foi avaliada 
pelo teste de Sperman e com mortalidade pelo teste de Mann-
-Whitney. Os resultados foram considerados significativos se 
p<0,05. 
Resultados: Foram incluídos 21 pacientes e feitas 60 coletas 
para avaliação da homocisteina total (mediana de 6,92 (5,27 
- 9,74 μmol/l). O teste de correlação Spearman não mostrou 
associação entre homocisteina e SOFA (r = -0,15 e p = 0,26). 
Também não foi encontrada correlação da medida de homo-
cisteína na data de admissão do estudo e a diferença do SOFA 
obtido no 3º dia e o SOFA da admissão (deltaSOFA) (r = 0,04 
e p = 0,87). A variação da homocisteína do 3º dia e a admissão 
no estudo (deltaHmc) e a variação do SOFA no mesmo perí-
odo não estavam correlacionadas (r = -0,11 e p = 0,66). A ho-
mocisteina da admissão não se correlacionou com mortalidade 
na UTI (p=0,46) ou com a mortalidade hospitalar.(p=0,13). 
Mesmo quando foi utilizado o deltaHmc não houve correlação 
(p=012 e p=0,99, respectivamente).
Conclusão: O nível basal de homocisteína ou sua variação 
nos primeiros dias da disfunção não estiveram relacionadas com 
a piora dos parâmetros funcionais dos sistemas orgânicos ou 
mortalidade nos pacientes sépticos.
Descritores: Homocisteina; Sepse; Disfunção orgânica; 
Mortalidade
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